-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novo Nordisk conducted a post-analysis on the trial data of LEADER, SUSTAIN 6 and PIONEER 6 in three large cardiovascular outcome studies.
After a median follow-up time of 3.
6 years, 47 people were found to have dementia (early mild Alzheimer's disease).
), 32 of them used a placebo and 15 used GLP-1 drugs (liraglutide or simaglutide)
.
From a statistical point of view, the incidence of dementia was significantly reduced by 53%, thereby providing further clinical evidence for GLP-1 to treat dementia
.
Novo Nordisk initiated two key Phase III studies of 3700 patients with early-stage Alzheimer's disease, mainly to evaluate the efficacy and safety of oral smeglutide (14 mg, once a day) compared with placebo in the treatment of early-stage AD Sexual difference, the administration time is expected to last about 2 years
.
Previously, there were only 5 drugs used in the clinical treatment of AD in the world, and most of them were only for symptom control, including memantine, etc.
, until the advent of GV-971 of Green Valley Pharmaceuticals broke the deadlock of no new drugs on the market in the field of AD treatment for 17 years.
Although this drug was controversial, it was sold out soon after it was launched
.
The research and development of new drugs is not easy, and the huge unmet need for treatment is also accompanied by huge research and development risks
.
